ACIP Dengue Vaccines
Workgroup

Robert Atmar, MD
ACIP Member and Workgroup Chair
ACIP Meeting October 24, 2019
ACIP Dengue Vaccines Workgroup

ACIP Members
Robert Atmar (Chair)
Beth Bell
Veronica McNally
Kathy Poehling

Ex Officio Members
Marc Challberg (NIH)
Doran Fink (FDA)
Kirk Prutzman (FDA)
Seshadri Srihari (DOD)

CDC Lead
Steve Waterman
Gabriela Paz-Bailey (Co-Lead)

Liaison Representatives
Elizabeth Barnett (AAP)
Rob Schechter (AIM)

Consultants
Edwin Asturias
Alan Barrett
Anna Durbin
Ines Esquilin
Tony Marfin
Hal Margolis
Kristen Pierce
Anita Shet

CDC Contributors
Laura Adams
Mimi Eckert
Rachel Eidex
Marc Fischer
Susan Hills
Terri Hyde
Mike McNeil
Jorge Munoz
Cindy Weinbaum
Dengue Vaccines Workgroup Discussions
July-October 2019

- Dengue vaccines in seronegative individuals: new insights from vaccine trials and laboratory research
- Perspective on partially effective vaccines
- Dengvaxia implementation feasibility in Puerto Rico
- Orientation of new members to previous WG discussions
- Cost effectiveness of CYD-TDV in Puerto Rico
- CYD-TDV GRADE analysis
ACIP Dengue Vaccines Workgroup

ACIP October 2019 Presentations

GRADE Analysis for Dengvaxia

Gabriela Paz-Bailey, CDC Dengue Branch

Dengvaxia Cost Effectiveness in Puerto Rico

Alex Perkins, University of Notre Dame

Summary of Workgroup Discussions and Next Steps

Steve Waterman, CDC Dengue Branch
ACIP Dengue Vaccines Workgroup

- Anticipated ACIP Schedule 2020
  - February 2020–Dengvaxia acceptability and feasibility in Puerto Rico; Evidence to recommendations
  - June 2020- TBD